Children's Mercy Kansas City

SHARE @ Children's Mercy
Manuscripts, Articles, Book Chapters and Other Papers
12-2020

Treatment-Induced Neuropathy of Diabetes in Youth: Case Series
of a Heterogeneous and Challenging Complication.
Eirene G. Alexandrou
Sarah D. Corathers
Amit Lahoti
Jacob M. Redel
Children's Mercy Hospital

Siobhan Tellez

See next page for additional authors

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers
Part of the Endocrinology, Diabetes, and Metabolism Commons, and the Pediatrics Commons

Recommended Citation
Alexandrou EG, Corathers SD, Lahoti A, et al. Treatment-Induced Neuropathy of Diabetes in Youth: Case
Series of a Heterogeneous and Challenging Complication. J Endocr Soc. 2020;4(12):bvaa154. Published
2020 Oct 15. doi:10.1210/jendso/bvaa154

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for
inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @
Children's Mercy. For more information, please contact library@cmh.edu.

Creator(s)
Eirene G. Alexandrou, Sarah D. Corathers, Amit Lahoti, Jacob M. Redel, Siobhan Tellez, Nana-Hawa Yayah
Jones, and Ahlee Kim

This article is available at SHARE @ Children's Mercy: https://scholarlyexchange.childrensmercy.org/papers/2705

Journal of the Endocrine Society, 2020, Vol. 4, No. 12, 1–6
doi:10.1210/jendso/bvaa154
Case Report

Case Report

Eirene G. Alexandrou,1,2 Sarah D. Corathers,3,4 Amit Lahoti,5,6 Jacob Redel,7,8
Siobhan Tellez,3 Nana-Hawa Yayah Jones,3,4 and Ahlee Kim5,6
1

Division of Endocrinology, University of Iowa Stead Family Children’s Hospital, Iowa City, Iowa 52242;
Department of Pediatrics, University of Iowa, Iowa City, Iowa 52242; 3Division of Endocrinology, Cincinnati
Children’s Hospital Medical Center, Cincinnati, Ohio 45229; 4Department of Pediatrics, University of Cincinnati,
Cincinnati, Ohio 45229; 5Division of Endocrinology, Le Bonheur Children’s Hospital, Memphis, Tennessee
38103; 6Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee
38103; 7Division of Endocrinology, Children’s Mercy Hospital, Kansas City, Missouri 64108; and 8Department of
Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri 64108
2

ORCiD numbers: 0000-0003-0039-8701 (A. Lahoti); 0000-0003-3978-8491 (J. Redel); 0000-0002-3631-0313 (S. Tellez);
0000-0002-9988-6686 (N.-H. Yayah Jones); 0000-0002-2620-5501 (A. Kim).
Abbreviations: DKA, diabetic ketoacidosis; DPN, diabetic polyneuropathy; HbA1c, glycosylated hemoglobin A1c; MDI,
multiple daily injection; MRI, magnetic resonance imaging; T1D, type 1 diabetes; T2D, type 2 diabetes; TIND, treatmentinduced neuropathy of diabetes.
Received: 1 September 2020; Editorial Decision: 6 October 2020; First Published Online: 15 October 2020; Corrected and
Typeset: 7 November 2020.

Abstract
Treatment-induced neuropathy of diabetes (TIND) is a small fiber neuropathy precipitated by rapid correction of hyperglycemia. Literature on TIND in pediatric diabetes
is scarce. We present 7 cases of TIND in children and young adults, increasing awareness of this condition in pediatric diabetes and broadening the scope of published
knowledge.
Key Words: pediatric diabetes, diabetes complications, pain, diabetic neuropathy, somatic pain

Treatment-induced neuropathy of diabetes (TIND),
first described in 1933, is a painful somatosensory and
autonomic neuropathy occurring with rapid improvement in glycemic control (>2% decline in glycosylated
hemoglobin A1c [HbA1c] over 3 months) achieved by
insulin, oral hypoglycemic agents, or severe dietary
restriction in patients with recent or remote type 1
(T1D) and type 2 diabetes (T2D) [1-3]. Neuropathic

symptoms are described as either burning, freezing, tingling, stinging, or allodynia, follow a symmetric distribution, and are worse distally. Risk factors include
higher baseline HbA1c (>10% or 86 mmol/mol), diabetic anorexia or weight loss, and female gender [3, 4].
TIND is distinct from diabetic polyneuropathy (DPN),
given its acute onset and often reversible nature. TIND
is also associated with autonomic dysfunction and
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Case Descriptions

resolved over 4 months without treatment or worsening
glycemic control.

Case 2
A 16-year-old Caucasian female presented with DKA and
new-onset T1D with HbA1c >14% (>130 mmol/mol). MDI
insulin therapy was initiated. Generalized insulin edema
with pleural effusions developed within 1 week, marked by
an 18 kg weight gain that improved with diuretics. Over
4 weeks, her HbA1c improved to 9.9% (85 mmol/mol), at
which time she developed pain and paresthesia of her chest,
abdomen, back, hands, and feet. She reported early satiety
with an 11 kg weight loss over 3 months and palpitations.
Bilateral, moderate nonproliferative retinopathy, macular
edema, and cataracts were also noted at T1D diagnosis.
Additional screening for microvascular complications revealed microalbuminuria. Her evaluation was negative for
pancreatitis, urinary tract infection, nephrolithiasis, and
celiac disease. She had normal iron studies and inflammatory markers, and no vitamin deficiencies. A gastric
emptying study revealed gastroparesis. Her electrocardiogram was notable for sinus tachycardia and echocardiogram was normal. She had normal muscle strength, deep
tendon reflexes, and sensation to touch, temperature, vibration, and proprioception. Neurology diagnosed her
with TIND and initiated gabapentin. Situational tachycardia was suspected, but over the next several months
she experienced palpitations that awakened her from sleep
and occurred at rest. Due to concerns for dysautonomia
she was referred back for cardiologic consultation, but she
did not follow up. With improved glycemic control over
the next 6 months her neuropathy, autonomic symptoms,
and microvascular manifestations subsided, and medications were tapered off.

Case 1
A 14-year-old African American male presented with diabetic ketoacidosis (DKA) and new-onset T1D with initial
HbA1c>14% (>130 mmol/mol). With multiple daily injection (MDI) insulin therapy, his HbA1c declined to 5.6%
(38 mmol/mol) after 3 months. Simultaneously, burning
and allodynia developed in his chest, abdomen, and lower
extremities as well as early satiety with a 4 kg weight loss.
Evaluation for weight loss demonstrated normal adrenal,
thyroid, liver, and renal function, and was negative for inflammatory bowel disease. Over the next few months, his
appetite normalized, and he regained 8 kg. His pain was
discussed with rheumatology and neurology, and presentation was deemed consistent with TIND. Low-dose
gabapentin was offered, but not pursued. His symptoms

Case 3
A 19-year-old Caucasian male with a five-year history of
poorly controlled T1D was motivated to improve glycemic
control. In 1 month, his HbA1c declined from 12.1%
(109 mmol/mol) to 8.6% (70 mmol/mol). He developed
burning pain in his feet and early satiety with a 3 kg weight
loss. His exam was notable for normal muscle strength,
deep tendon reflexes, and sensation to light touch and proprioception. He had mildly decreased vibration sensation in
his feet with tenderness of the plantar surfaces. Neurology
diagnosed him with TIND and started gabapentin along
with cognitive behavioral therapy. His pain was refractory
to treatment and he was subsequently lost to follow-up.
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microvascular complications, underscoring the importance of an interdisciplinary approach to care [4, 5].
Current management, including gabapentinoids, tricyclics, or serotonin reuptake inhibitors, is limited by
our understanding of TIND pathophysiology [4-6],
of which there are a few postulated mechanisms. One
theory relates to hyperglycemia-induced microcirculatory changes that cannot remodel at the same rate of
decline in serum glucose, leading to ischemic conditions
within the endoneurium. Another thought is that acute
glucose deprivation leads to cellular apoptosis and, once
a normoglycemic state is achieved, the subsequent firing
of regenerating axons results in the development of
neuropathic symptoms [4]. Treatment response in TIND
is variable with a gradual (but sometimes incomplete)
resolution of symptoms over 3 to 24 months [4-6]. Cases
of TIND are well described in adult literature, and a recent report has shown that 11% of patients (n = 954) referred to a diabetic neuropathy clinic had presentations
consistent with TIND [3]. The prevalence in children remains unclear, as pediatric literature is scarce, with only
2 cases reported [4, 7].
In this series, we describe 7 cases of TIND in children and young adults treated at 2 pediatric centers
(Cincinnati Children’s Hospital Medical Center and Le
Bonheur Children’s Hospital). We aim to promote recognition of this condition, especially within the pediatric community. Additionally, we look to broaden the
scope of published knowledge regarding TIND, highlight
its varied course and treatment challenges, and inspire
continued research in the area to better define TIND so
that novel prevention and treatment strategies can be
developed.

3
One year later, he returned to the endocrine clinic with
HbA1c 6.5% (48 mmol/mol) and no complaints of pain or
early satiety off medication.
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2 years prior. His HbA1c remains between 6% and 8.5%
(42-69 mmol/mol).

Case 6
Case 4

Case 5
A 19-year-old Caucasian male with a 3-year history of
poorly controlled T1D reinitiated consistent MDI insulin therapy. Over 2 months, his HbA1c decreased from
>14% (>130 mmol/mol) to 8.3% (67 mmol/mol). He
developed burning pain in his extremities, torso, and
perineum, and profuse diarrhea with emesis. He lost 8
kg over 5.5 months, resulting in admission. Evaluation
demonstrated normal esophagogastroduodenoscopy, colonoscopy, gastric emptying scan, and magnetic resonance
imaging (MRI) of abdomen and pelvis. He had a negative
celiac screen, nonelevated secretory diarrhea hormones,
negative bacterial overgrowth test, negative infectious
workup, normal inflammatory markers, normal thyroid testing, and negative rheumatologic markers. He
was diagnosed with diabetic enteric neuropathy and
TIND, and started on medical therapy (Table 1). He developed restrictive eating behaviors given concern for
worsening diarrhea and body image issues, and he was
later diagnosed with anorexia nervosa. Within 3 months
of his neuropathic symptoms, he also developed
microalbuminuria, which is ongoing. He has continued
medications for symptom management since initiation

A 9-year-old Caucasian female was admitted with severe
DKA and in a coma due to medical neglect 1 month postT1D diagnosis. Her HbA1c was >14% (>130 mmol/mol).
She reinitiated MDI insulin therapy upon discharge with her
foster family. Over 1 month, her glycemic control improved
to HbA1c 6% (42 mmol/mol), she developed paresthesia of
her lower extremities, incontinence, and reported difficulties in walking as well as a 14 kg weight loss. Her exam was
remarkable for pain to palpation of right lower extremity,
decreased strength of right dorsiflexor and plantar flexor,
and right foot drop. Deep tendon reflexes were intact. Spine
MRI was normal. She was diagnosed with TIND and referred to physical medicine and rehabilitation, but did not
follow up. All symptoms resolved without intervention
over 3 months. Her HbA1c has ranged from 6% to 6.2%
(42-44 mmol/mol).

Case 7
A 17-year-old Caucasian male with new-onset,
antibody-negative T1D was started on MDI insulin
therapy. His glycemic control improved from HbA1c >14%
(>130 mmol/mol) to 10.7% (93 mmol/mol) over 4 weeks.
He developed allodynia and paresthesia in his lower extremities and scrotum, and a decreased appetite with 10 kg
weight loss. Microalbuminuria and mild, nonproliferative
retinopathy developed. He had a normal spine MRI and a
delayed gastric emptying scan. His presentation was consistent with TIND, and he was started on gabapentin and
self-initiated cannabis. His symptoms persisted, so treatment was modified (Table 1). He had gradual resolution of
all symptoms over 10 months, aside from unchanged retinopathy, and he discontinued all noninsulin medications.
His HbA1c remains <6% (<42 mmol/mol).

Discussion
In this series we describe 7 cases of TIND in children and
young adults treated at 2 pediatric centers, increasing recognition of TIND as a complication of pediatric diabetes.
Prior to our report, only 2 pediatric cases had been published [4, 7], indicating that the occurrence of TIND is
more than the paucity of literature suggests. By raising
awareness, we hope to enhance detection and timely management of this distressing and potentially debilitating
condition. TIND should be considered in patients with
diabetes who present with acute neuropathy or autonomic
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A 22-year-old African American male with a 3-year
history of poorly controlled T1D with HbA1c >14%
(>130 mmol/mol) was transitioned to insulin pump
therapy. Over 2 months, his HbA1c improved to 10.5%
(91 mmol/mol). Pain in his lower extremities and genitalia developed without associated impotence or urinary
symptoms. Evaluation was performed by urology, pain
team, and neurology. A computed tomography scan of
abdomen and pelvis, testicular ultrasound, and infectious
and lymphoproliferative disease workup was unremarkable. Deep tendon reflexes were symmetrically depressed
at his knees and ankles. His pain was refractory to
gabapentin, but improved modestly with acupuncture.
He experienced a 4.5 kg weight loss attributed to decreased appetite and intermittent emesis in setting of
severe pain. Given the unremitting pain, he developed depression and was started on duloxetine. Over 5 months,
his HbA1c rose to 13.5% (124 mmol/mol) and symptoms resolved. His glycemic control gradually improved,
and he has maintained a HbA1c near 10% (86 mmol/
mol) without return of symptoms.

Age at
TIND
onset
(years)

14

16

19

22

19

9

17

Case 1

Case 2

Case 3

Case 4

Case 5

Case 6

Case 7

Pain pattern

Management

TIND
resolution
time

Autonomic
symptoms

Microvascular
complications

3 months Male

38.8 to
34/1.5 months

GAA

3–4 months Early satiety and None to date
>14% (130 mmol/ Burning sensation in Self-resolved
weight loss
chest, abdomen,
mol) to 5.6%
and lower
(38 mmol/
extremities
mol)/3 months
Microalbuminuria,
4 weeks Female 71.1 to 59.6/3
IA-2, ZnT8 >14% (130 mmol/ Burning sensation, Gabapentin up to 300mg daily, 6 months Early satiety,
bilateral moderate
cyproheptadine 4mg daily
delayed gastric
numbness, and
months
mol) to 9.9%
nonproliferative
emptying,
tingling in chest,
(85 mmol/
retinopathy with
weight loss,
abdomen, lower
mol)/1 month
macular edema
and sinus
back, hands, and
(OD > OS) and
tachycardia
feet
cataracts
12 months Early satiety and None to date
5 years
Male
76.2 to
IA-2, IAA 12.1% (109 mmol/ Bilateral burning and Gabapentin up to 1200mg
daily
weight loss
tingling sensation
73.1/2 months
mol) to 8.6%
in feet
(70 mmol/
mol)/1 month
None to date
3 years
Male
66 to
GAA, IA-2, >14% (130mmol/ Sharp pain in lower Gabapentin up to 900mg daily 5 months Early satiety,
recurrent
extremities,
61.6/4.5 months
ZnT8
mol) to 10.5%
emesis, and
perineum, and
(91mmol/
weight loss
scrotum
mol)/2 months
Microalbuminuria
N/A
Enteric
3 years
Male
56.7 to
GAA
>14% (130mmol/ Pain in extremities, Gabapentin up to 2400mg
neuropathy
daily, clonidine 0.1mg daily,
hip, trunk, and
48.6/5.5 months
mol) to 8.3%
with diarrhea
methocarbamol 500mg
perineum
(67mmol/
and weight
3 times daily, loperamide
mol)/2 months
loss
6mg 3 times daily
3 months Fecal and urinary None to date
2 months Female 48 to
GAA, IAA >14% (130mmol/ Weakness, tingling, Self-resolved
incontinence
numbness, and
33.9/1.5 months
mol) to 6%
and weight
sharp pain in
(42mmol/
loss
lower extremities
mol)/1 month
10 months Early satiety and Microalbuminuria,
Gabapentin up to 1800mg
4 weeks Male
58 to
Negative
>14% (130mmol/ Hypersensitivity,
weight loss
mild
daily; switched to
burning, and
48.4/3 months
mol) to 10.7%
nonproliferative
pregabalin 300mg daily,
tinging in
(93mmol/
retinopathy
erythromycin 100mg
scrotum, thighs,
mol)/1 month
3 times daily, and
legs, and soles
cyproheptadine 4mg twice
of feet
daily

Antibodies Change in
Duration Gender Change
in weight (kg)/ time
HbA1c/time
of
diabetes
at TIND
onset
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Cases

Table 1. Demographics, Anthropometrics, Diabetes History, Presentation of Pain With Associated Manifestations, and Treatments Utilized for Each Case
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unable to explain the variable and at times incomplete
response to treatment. This may be driven by underlying
genetic modifiers that have yet to be elucidated or could
also be a reflection of the lower doses of gabapentin prescribed, in contrast to a maximum daily dose of 3600 mg
[11]. Furthermore, the most severe and persistent presentation (case 5) also had anorexia nervosa, which may have
played a role in stagnating his recovery.
Although our cases clearly describe characteristics of
pediatric TIND, reporting on its prevalence is beyond the
scope of this series, as cases were identified through individual providers as opposed to unbiased, retrospective
chart review. We speculate that the condition may occur
more commonly in those with new-onset diabetes, as initiation of insulin results in rapid improvements in glycemic
control in contrast to a patient who has been on insulin
for several years (unless adherence to therapy changes).
Despite the estimated incidence of diabetes nearing 34.2
per 100 000 youths per year [12], reasons as to why TIND
is not more commonly reported, especially in comparison
to adults, demonstrates the need for further scientific exploration. Part of this could be driven by under-reporting
of symptoms in a pediatric population. The detection of
neuropathic symptoms may improve by standardized application of screening tools with age-appropriate language
for those presenting with rapidly improved glycemic control. Additional studies are also needed to determine genetic predisposition to TIND as well as other modifiers that
may endow protection in youth with diabetes.
At this time, we remain underpowered to define any
additional risk factors in TIND development or propose
novel prevention and treatment strategies. Gradual control of hyperglycemia was speculated as a potential preventive measure for TIND; however, this has never been
studied. Therefore, patients with diabetes should continue
to be approached according to guidelines, with aggressive
insulin therapy to reduce the risk of development and progression of microvascular complications [9]. Secondly, in
those that develop TIND, permissive hyperglycemia for
symptomatic resolution is inadvisable, given the increased
risk of permanent microvascular complications [6]. There
remain no consensus guidelines for management of TIND
and the approach to these patients, as evidenced by our
cases, continues to be varied. Our cases demonstrate that
extensive evaluation, including sophisticated imaging, may
be pursued; however, nearly all these studies were negative. This brings to light the need for established guidelines
to streamline diagnostic workup, while promoting timely
identification of TIND and minimizing the burden placed
on patients, providers, and the medical system by excessive diagnostics. Until future studies can further elucidate
the mechanisms contributing to TIND, the mainstay of
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symptoms following rapid correction of hyperglycemia defined as >2% decline in HbA1c over 3 months. If TIND
is suspected, interdisciplinary care comprised of an endocrinologist, neurologist, and pain management physician or
physical therapist should be coordinated.
Our cases reinforce the inciting events in TIND development, its varied course, unique treatment challenges,
and continued limitations. In accordance with previous
reports [1-8], all of our patients with TIND had a significantly elevated baseline HbA1c ranging from 12.1% to
>14% (109 mmol/mol to >130 mmol/mol) with a >2%
decline over 1 to 3 months (Table 1). TIND impacted both
those with recent and remote diabetes. Within our population, 57% had new-onset diabetes and the remaining
had lived with diabetes for 3 to 5 years. Despite the preponderance of T1D within our group, clinicians should
remain cognizant that this condition also impacts those
with T2D. Our cases also underscore the medical complexity of TIND. All presentations were complicated by
autonomic symptoms (gastrointestinal 100%; cardiovascular 14%; genitourinary 14%). Microvascular complications were also present in 43% of our patients; all had
microalbuminuria and 2 out of the 3 had nonproliferative
retinopathy. For those patients that were not due for microvascular screening per American Diabetes Association
guidelines [9], testing was performed only if symptoms
were expressed, such as retinal screening for those with
vision changes. Patients with retinal changes subsequently
had microalbuminuria screening, as the presence of one
microvascular complication may indicate another. The
early microvascular changes detected in our patients with
new-onset diabetes highlights the importance of screening
for these conditions in all TIND presentations, despite duration of diabetes. Another unique finding was the presence
of motor symptoms in 2 patients (cases 4 and 6). The loss
of motor axons associated with neurogenic muscle atrophy
has been documented as a late consequence of DPN [10];
however, motor deficits have yet to be reported in TIND.
Although case 4 had 3 years of poorly controlled diabetes,
the acute onset and resolution of his neuropathic and sensorimotor symptoms is inconsistent with DPN. Given our
limited understanding of TIND’s pathophysiology, small
sample size, and the challenge of performing neurological
exams in young children, we are unable to definitively
conclude if motor deficit is a new, underrecognized manifestation of pediatric TIND. Lastly, treatment response in
this condition is varied, as shown here. Some of our patients experienced spontaneous resolution of symptoms
without treatment or worsening glycemic control (29%),
while others experienced resolution of pain within 5 to
12 months of starting medical therapy (57%) or unremitting pain despite intervention (14%) (Table 1). We are
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treatment continues to be supportive care and stable glycemic control within recommended targets [4, 12].
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